GlycoMimetics, Inc. (GLYC)
NASDAQ: GLYC · Real-Time Price · USD
0.2023
-0.0077 (-3.67%)
Apr 1, 2025, 10:34 AM EDT - Market open
GlycoMimetics Employees
GlycoMimetics had 4 employees as of December 31, 2024. The number of employees decreased by 31 or -88.57% compared to the previous year.
Employees
4
Change (1Y)
-31
Growth (1Y)
-88.57%
Revenue / Employee
n/a
Profits / Employee
-$9,469,790
Market Cap
13.05M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GLYC News
- 26 days ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders - PRNewsWire
- 4 weeks ago - Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 5 months ago - Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 - PRNewsWire
- 5 months ago - GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting - Business Wire
- 5 months ago - GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC - Business Wire
- 5 months ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders - PRNewsWire
- 5 months ago - GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma - Business Wire
- 5 months ago - GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint - Business Wire